Does TALIMOGENE LAHERPAREPVEC Cause Malignant neoplasm progression? 16 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 16 reports of Malignant neoplasm progression have been filed in association with TALIMOGENE LAHERPAREPVEC (Imlygic). This represents 1.1% of all adverse event reports for TALIMOGENE LAHERPAREPVEC.
16
Reports of Malignant neoplasm progression with TALIMOGENE LAHERPAREPVEC
1.1%
of all TALIMOGENE LAHERPAREPVEC reports
4
Deaths
2
Hospitalizations
How Dangerous Is Malignant neoplasm progression From TALIMOGENE LAHERPAREPVEC?
Of the 16 reports, 4 (25.0%) resulted in death, 2 (12.5%) required hospitalization.
Is Malignant neoplasm progression Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for TALIMOGENE LAHERPAREPVEC. However, 16 reports have been filed with the FAERS database.
What Other Side Effects Does TALIMOGENE LAHERPAREPVEC Cause?
Off label use (196)
Pyrexia (135)
Product storage error (133)
Metastatic malignant melanoma (109)
Circumstance or information capable of leading to medication error (89)
Death (82)
Influenza like illness (82)
Fatigue (70)
Chills (68)
Malignant melanoma (64)
What Other Drugs Cause Malignant neoplasm progression?
PEMBROLIZUMAB (10,111)
NIVOLUMAB (9,363)
ENZALUTAMIDE (4,696)
CARBOPLATIN (4,177)
EVEROLIMUS (3,789)
PACLITAXEL (3,484)
LETROZOLE (3,445)
IPILIMUMAB (3,296)
FULVESTRANT (3,221)
LENVATINIB (2,929)
Which TALIMOGENE LAHERPAREPVEC Alternatives Have Lower Malignant neoplasm progression Risk?
TALIMOGENE LAHERPAREPVEC vs TALQUETAMAB
TALIMOGENE LAHERPAREPVEC vs TALQUETAMAB-TGVS
TALIMOGENE LAHERPAREPVEC vs TAMIFLU
TALIMOGENE LAHERPAREPVEC vs TAMOXIFEN
TALIMOGENE LAHERPAREPVEC vs TAMSULOSIN